Market closed
MiNK Therapeutics/$INKT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About MiNK Therapeutics
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.
Ticker
$INKT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
31
Website
INKT Metrics
BasicAdvanced
$26M
Market cap
-
P/E ratio
-$0.38
EPS
0.05
Beta
-
Dividend rate
Price and volume
Market cap
$26M
Beta
0.05
52-week high
$1.90
52-week low
$0.57
Average daily volume
38K
Financial strength
Current ratio
0.889
Quick ratio
0.855
Long term debt to equity
-26.271
Total debt to equity
-26.271
Management effectiveness
Return on assets (TTM)
-120.36%
Return on equity (TTM)
88.52%
Valuation
Price to book
-1.49
Price to tangible book (TTM)
-1.49
Price to free cash flow (TTM)
-2.223
Growth
Earnings per share change (TTM)
-47.88%
3-year earnings per share growth (CAGR)
-29.42%
What the Analysts think about INKT
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for MiNK Therapeutics stock.
INKT Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
INKT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
INKT News
AllArticlesVideos
MiNK Therapeutics, Inc. (INKT) Q3 2024 Earnings Conference Call Transcript
Seeking Alpha·4 weeks ago
MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report
GlobeNewsWire·1 month ago
MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for MiNK Therapeutics stock?
MiNK Therapeutics (INKT) has a market cap of $26M as of December 12, 2024.
What is the P/E ratio for MiNK Therapeutics stock?
The price to earnings (P/E) ratio for MiNK Therapeutics (INKT) stock is 0 as of December 12, 2024.
Does MiNK Therapeutics stock pay dividends?
No, MiNK Therapeutics (INKT) stock does not pay dividends to its shareholders as of December 12, 2024.
When is the next MiNK Therapeutics dividend payment date?
MiNK Therapeutics (INKT) stock does not pay dividends to its shareholders.
What is the beta indicator for MiNK Therapeutics?
MiNK Therapeutics (INKT) has a beta rating of 0.05. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.